Edgewise Therapeutics, Inc. (EWTX)

Over the past six months, Edgewise Therapeutics' stock has experienced significant positive movement, with a 113.53% increase over the past year. Key events impacting the stock price include positive long-term Sevasemten data, inducement stock options grants to new non-executive employees, presentations at healthcare conferences, and the release of fourth quarter and full year 2025 financial results.

As a clinical-stage biopharmaceutical company, Edgewise Therapeutics, Inc. does not currently have commercialized products or services with traditional demand seasonality. However, implied volatility for EWTX stock has shown some historical seasonal patterns, tending to rise most in November and decline to its lowest levels in March.

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for severe, rare neuromuscular and cardiac disorders. The company operates within the Healthcare sector and Biotechnology industry, employing a holistic drug discovery approach focused on identifying small molecule precision medicines. Its major product candidates include Sevasemten (EDG-5506), EDG-7500, and EDG-15400.

Edgewise Therapeutics, Inc. is headquartered in Boulder, Colorado, United States, with operations and market focus primarily within the United States.

In the past year, Edgewise Therapeutics has maintained a positive brand reputation, driven by positive clinical developments. The company has received a consensus rating of "Moderate Buy" from analysts, with an average rating score of 2.90. The positive long-term data for Sevasemten in Becker muscular dystrophy likely enhanced the company's reputation.

Edgewise Therapeutics, Inc. has a diverse ownership structure, with a significant portion held by institutional investors, approximately 76.36% to 88.61%. Insiders hold around 1.38% to 14.60% of the stock, while retail investors hold approximately 2.03%. Major institutional owners include OrbiMed Advisors LLC, RA Capital Management, L.P., and BlackRock, Inc. Peter Kolchinsky and Holdings A. Novo are also significant shareholders.